Prospective, Multicenter, Open-label Study Evaluating the Effects of First-line Oral Combination Therapy of Macitentan and Tadalafil in Patients With Newly Diagnosed Pulmonary Arterial Hypertension (OPTIMA).

Trial Profile

Prospective, Multicenter, Open-label Study Evaluating the Effects of First-line Oral Combination Therapy of Macitentan and Tadalafil in Patients With Newly Diagnosed Pulmonary Arterial Hypertension (OPTIMA).

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 04 Dec 2017

At a glance

  • Drugs Macitentan (Primary) ; Tadalafil
  • Indications Pulmonary arterial hypertension
  • Focus Therapeutic Use
  • Acronyms OPTIMA
  • Sponsors Actelion Pharmaceuticals
  • Most Recent Events

    • 28 Nov 2017 Planned End Date changed from 1 Nov 2017 to 1 Apr 2020.
    • 28 Nov 2017 Planned primary completion date changed from 1 Nov 2017 to 1 Apr 2018.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top